Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITK | Q08881 | 14/20 | 0.55 |
| ▸ | LCK | P06239 | 3/20 | 0.55 |
| ▸ | TXK | P42681 | 3/20 | 0.55 |
| ▸ | SYK | P43405 | 3/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.38 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.38 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.38 |
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
| ▸ | FER | P16591 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | MARK3 | P27448 | 1/20 | 0.38 |
| ▸ | FLT4 | P35916 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 1/20 | 0.38 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.38 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.38 |
| ▸ | CLK2 | P49760 | 1/20 | 0.38 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1628603 | 0.82 | ITK (0.62) | ITKLCKTXKSYKAURKB | |
| SCHEMBL1622468 | 0.81 | ITK (0.57) | ITKLCKTXKSYKCHEK1 | |
| SCHEMBL2900919 | 0.80 | CYP19A1 (0.44) | ITKLCKTXKSYKCYP19A1 | |
| SCHEMBL27645976 | 0.80 | ITK (0.54) | ITKLCKTXKSYKCSNK2A1 | |
| SCHEMBL1620556 | 0.77 | ITK (0.51) | ITKLCKTXKSYKCHEK1 | |
| SCHEMBL1623956 | 0.76 | ITK (0.58) | ITKLCKTXKSYKCHEK1 | |
| SCHEMBL1623125 | 0.76 | ITK (0.50) | ITKLCKTXKSYK | |
| SCHEMBL1621994 | 0.75 | ITK (0.72) | ITKLCKTXKSYKCHEK1 | |
| SCHEMBL1622893 | 0.75 | ITK (0.72) | ITKLCKTXKSYKCHEK1 | |
| SCHEMBL1622709 | 0.75 | ITK (0.72) | ITKLCKTXKSYKCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1682553-B1 | THIENOPYRAZOLES | AVENTIS PHARMA INC (US) | 2010-05-19 | — | — | EP | claimed |
| US-20100056514-A1 | THIENOPYRAZOLES | AVENTIS PHARMACEUTICALS INC. (US) | 2010-03-04 | — | — | US | claimed |
| US-7518000-B2 | Thienopyrazoles | AVENTIS PHARMACEUTICALS, INC. (US) | 2009-04-14 | — | — | US | claimed |
| CN-100398545-C | Thienopyrazoles | AVENTIS PHARMA INC (US) | 2008-07-02 | — | — | CN | claimed |
| US-20070254937-A1 | Thienopyrazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2007-11-01 | — | — | US | claimed |
| JP-2007505038-A | — | — | 2007-03-08 | — | — | JP | claimed |
| CN-1849322-A | Thienopyrazoles | AVENTIS PHARMA INC (US) | 2006-10-18 | — | — | CN | claimed |
| EP-1682553-A1 | THIENOPYRAZOLES | Aventis Pharmaceuticals Inc. (US) | 2006-07-26 | — | — | EP | claimed |
| WO-2005026175-A1 | THIENOPYRAZOLES | AVENTIS PHARMACEUTICALS INC. (US) | 2005-03-24 | — | — | WO | claimed |
| US-7928231-B2 | Thienopyrazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2011-04-19 | — | — | US | disclosed |
| US-7928231-B2 | Thienopyrazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2011-04-19 | — | — | US | disclosed |
| US-7928231-B2 | Thienopyrazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2011-04-19 | — | — | US | disclosed |
| EP-1682553-B1 | THIENOPYRAZOLES | AVENTIS PHARMA INC (US) | 2010-05-19 | — | — | EP | disclosed |
| US-20100056514-A1 | THIENOPYRAZOLES | AVENTIS PHARMACEUTICALS INC. (US) | 2010-03-04 | — | — | US | disclosed |
| CN-100398545-C | Thienopyrazoles | AVENTIS PHARMA INC (US) | 2008-07-02 | — | — | CN | disclosed |
| US-20070254937-A1 | Thienopyrazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254937-A1 | Thienopyrazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2007-11-01 | — | — | US | disclosed |
| CN-1849322-A | Thienopyrazoles | AVENTIS PHARMA INC (US) | 2006-10-18 | — | — | CN | disclosed |
| EP-1682553-A1 | THIENOPYRAZOLES | Aventis Pharmaceuticals Inc. (US) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005026175-A1 | THIENOPYRAZOLES | AVENTIS PHARMACEUTICALS INC. (US) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056514-A1 | THIENOPYRAZOLES | ITK, IL2, TYK2 | ITK 1/4885LCK 46/4885TXK 6/4885 |
| US-20070254937-A1 | Thienopyrazoles | ITK, IL2, JAK2 | ITK 1/4885LCK 59/4885TXK 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.